Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410–427.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Robak P, Robak T. Novel drugs for multiple myeloma. In: Atta-ur-Rahman ZK, editors. Topics in anti-cancer research. Vol. 8. Sharjah: Bentham Science Publishers; 2019. p. 1–43.
   Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–322.
   PubMed Web of Science ®Google Scholar
• Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):343–350.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132–147.
   PubMed Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-Related inflammation. J Clin Immunol. 2013;33(S1):79–84.
   Google Scholar
• Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1):160–172.
   PubMed Web of Science ®Google Scholar
• Pirozzolo G, Gisbertz SS, Castoro C, et al. Neutrophil-to-lymphocyte ratio as prognostic marker in esophageal cancer: a systematic review and meta-analysis. J Thorac Dis. 2019;11(7):3136–3145.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Hu ZG, Shi WX, et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroenterol. 2015;21(9):2807–2815.
   PubMed Web of Science ®Google Scholar
• Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014;134(10):2403–2413.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang G, Jiang X, et al. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. Atherosclerosis. 2014;234(1):206–213.
   PubMed Web of Science ®Google Scholar
• Huang Z, Fu Z, Huang W, et al. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis. Am J Emerg Med. 2020;38(3):641–647.
   PubMed Web of Science ®Google Scholar
• Huang WJ, Huang G-T, Zhan QM, et al. The neutrophil to lymphocyte ratio as a novel predictor of asthma and its exacerbation: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020;24(22):11719–11728.
   PubMed Web of Science ®Google Scholar
• Chan AS, Rout A. Use of neutrophil-to-Lymphocyte and platelet-to-Lymphocyte ratios in COVID-19. J Clin Med Res. 2020;12(7):448–453.
   PubMedGoogle Scholar
• Wang J, Zhou X, Liu Y, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: a meta-analysis. PLoS One. 2017;12(4):e0176008.
   PubMed Web of Science ®Google Scholar
• Marcheselli R, Bari A, Tadmor T, et al. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol. 2017;35(4):561–566.
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Cicic D, Stoos-Veic T, et al. Elevated neutrophil-to-Lymphocyte-ratio and platelet-to-Lymphocyte ratio in myelofibrosis: inflammatory biomarkers or representatives of myeloproliferation itself? Anticancer Res. 2018;38(5):3157–3163.
   PubMed Web of Science ®Google Scholar
• Stefaniuk P, Szymczyk A, Podhorecka M. The neutrophil to lymphocyte and lymphocyte to monocyte ratios as new prognostic factors in hematological Malignancies - A narrative review. Cancer Manag Res. 2020;12:2961–2977.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ B. 2016;(36):e418–e423.
   PubMedGoogle Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group. Blood. 2016;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Liu Z, Li Q, et al. Prognostic value of neutrophil to lymphocyte ratio and clinicopathological characteristics for multiple myeloma: a meta-analysis. Medicine (Baltimore). 2018;97(41):e12678.
   PubMed Web of Science ®Google Scholar
• Mu S, Ai L, Fan F, et al. Prognostic role of neutrophil-lymphocyte ratio in multiple myeloma: a dose-response meta-analysis. Onco Targets Ther. 2018;11:499–507.
   PubMed Web of Science ®Google Scholar
• Romano A, Parrinello NL, Consoli ML, et al. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol. 2015;94(11):1875–1883.
   PubMed Web of Science ®Google Scholar
• Szudy-Szczyrek A, Mlak R, Mielnik M, et al. Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. Ann Hematol. 2020;99(12):2881–2891.
   PubMed Web of Science ®Google Scholar
• Lee GW, Park SW, Go SI, et al. The derived neutrophil-to-Lymphocyte ratio Is an independent prognostic factor in transplantation ineligible patients with multiple myeloma. Acta Haematol. 2018;140(3):146–156.
   PubMed Web of Science ®Google Scholar
• Solmaz Medeni S, Acar C, Olgun A, et al. Can neutrophil-to-Lymphocyte ratio, monocyte-to-Lymphocyte ratio, and platelet-to-Lymphocyte ratio at day +100 be used as a prognostic marker in multiple myeloma patients with autologous transplantation? Clin Transplant. 2018;32(9):e13359.
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080.1.
   Google Scholar
• Austin PC, Brunner LJ. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat Med. 2004;23(7):1159–1178.
   PubMed Web of Science ®Google Scholar
• Cho H, Yoon DH, Lee JB, et al. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. Am J Hematol. 2017;92(12):1280–1286.
   PubMed Web of Science ®Google Scholar
• Lu J, Lu J, Liu A, et al. The applicability of the international staging system in Chinese patients with multiple myeloma receiving bortezomib or Thalidomide-based regimens as induction therapy: a multicenter analysis. Biomed Res Int. 2015;2015:856704.
   PubMed Web of Science ®Google Scholar
• González-Calle V, Slack A, Keane N, et al. Evaluation of revised international staging system (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018;97(8):1453–1462.
   PubMed Web of Science ®Google Scholar
• Ozaki S, Handa H, Saitoh T, et al. Evaluation of the revised international staging system (R-ISS) in japanese patients with multiple myeloma. Ann Hematol. 2019;98(7):1703–1711.
   PubMed Web of Science ®Google Scholar